Human Neural Stem Cells

Phase 1Cell therapy

AAzienda Ospedaliera Santa Maria, Terni, Italy

Human Neural Stem Cells is one of 77 biologic programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Secondary Progressive Multiple SclerosisActive, not recruiting

Amyotrophic Lateral SclerosisPhase 1

Active, not recruiting

Secondary Progressive Multiple SclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

220 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Radicava

Shionogi

Phase 3

2 3

Simdax

Orion Corporation, Orion Pharma

Phase 3

1 4

Robitussin

Ultomiris

Lithobid

SSolvay Pharmaceuticals

Phase 3

3 7

Minocin

TTriax

Phase 3

2 8

Sodium Valproate

AstraZeneca

Phase 3

1 9

BOTULINUM TOXIN TYPE B

Eisai

Phase 3

1 10

Actos

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS)

Completed·AAzienda Ospedaliera Santa Maria, Terni, Italy·Phase 1·NCT01640067·18 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients

Completed·CCasa Sollievo della Sofferenza IRCCS·Phase 1·NCT03282760·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Human Neural Stem Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human Neural Stem Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human Neural Stem Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azienda Ospedaliera Santa Maria, Terni, Italy company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: AAzienda Ospedaliera Santa Maria, Terni, Italy

Human Neural Stem Cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

Secondary Progressive Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News